Sign Up to like & get
recommendations!
0
Published in 2017 at "Cancer Gene Therapy"
DOI: 10.1038/cgt.2017.12
Abstract: The recombinant sTRAIL has been in clinical trial for various human malignancies. However, the half-life time of sTRAIL is very short, which might be an important factor influencing its clinical efficacy for cancer therapy. We…
read more here.
Keywords:
safety;
efficacy;
raav2 strail95;
strail95 281 ... See more keywords